|
1
|
Slupe AM, Merrill RA and Strack S:
Determinants for substrate specificity of protein phosphatase 2A.
Enzyme Res. 2011:3987512011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ruediger R, Roeckel D, Fait J, Bergqvist
A, Magnusson G and Walter G: Identification of binding sites on the
regulatory A subunit of protein phosphatase 2A for the catalytic C
subunit and for tumor antigens of simian virus 40 and polyomavirus.
Mol Cell Biol. 12:4872–4882. 1992.
|
|
3
|
Xu Y, Xing Y, Chen Y, Chao Y, Lin Z, Fan
E, Yu JW, Strack S, Jeffrey PD and Shi Y: Structure of the protein
phosphatase 2A holoenzyme. Cell. 127:1239–1251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Arroyo JD, Timmons JC, Possemato R
and Hahn WC: Cancer-associated PP2A Aalpha subunits induce
functional haploinsufficiency and tumorigenicity. Cancer Res.
65:8183–8192. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jones S, Wang TL, Shih IM, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McConechy MK, Anglesio MS, Kalloger SE,
Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, Mes-Masson AM,
et al; Australian Ovarian Cancer Study Group. Subtype-specific
mutation of PPP2R1A in endometrial and ovarian carcinomas. J
Pathol. 223:567–573. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nagendra DC, Burke J III, Maxwell GL and
Risinger JI: PPP2R1A mutations are common in the serous type of
endometrial cancer. Mol Carcinog. 51:826–831. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shih IM, Panuganti PK, Kuo KT, Mao TL,
Kuhn E, Jones S, Velculescu VE, Kurman RJ and Wang TL: Somatic
mutations of PPP2R1A in ovarian and uterine carcinomas. Am J
Pathol. 178:1442–1447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McConechy MK, Ding J, Cheang MC, Wiegand
KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, et al: Use
of mutation profiles to refine the classification of endometrial
carcinomas. J Pathol. 228:20–30. 2012.PubMed/NCBI
|
|
10
|
Calin GA, di Iasio MG, Caprini E,
Vorechovsky I, Natali PG, Sozzi G, Croce CM, Barbanti-Brodano G,
Russo G and Negrini M: Low frequency of alterations of the alpha
(PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the
serine-threonine phosphatase 2A in human neoplasms. Oncogene.
19:1191–1195. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ruteshouser EC, Ashworth LK and Huff V:
Absence of PPP2R1A mutations in Wilms tumor. Oncogene.
20:2050–2054. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang SS, Esplin ED, Li JL, Huang L, Gazdar
A, Minna J and Evans GA: Alterations of the PPP2R1B gene in human
lung and colon cancer. Science. 282:284–287. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takagi Y, Futamura M, Yamaguchi K, Aoki S,
Takahashi T and Saji S: Alterations of the PPP2R1B gene located at
11q23 in human colorectal cancers. Gut. 47:268–271. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tamaki M, Goi T, Hirono Y, Katayama K and
Yamaguchi A: PPP2R1B gene alterations inhibit interaction of
PP2A-Abeta and PP2A-C proteins in colorectal cancers. Oncol Rep.
11:655–659. 2004.PubMed/NCBI
|
|
15
|
Suraweera N, Robinson J, Volikos E,
Guenther T, Talbot I, Tomlinson I and Silver A: Mutations within
Wnt pathway genes in sporadic colorectal cancers and cell lines.
Int J Cancer. 119:1837–1842. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu R, Connolly DC, Ren X, Fearon ER and
Cho KR: Somatic mutations of the PPP2R1B candidate tumor suppressor
gene at chromosome 11q23 are infrequent in ovarian carcinomas.
Neoplasia. 1:311–314. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Campbell IG and Manolitsas T: Absence of
PPP2R1B gene alterations in primary ovarian cancers. Oncogene.
18:6367–6369. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marsh A, Healey S, Lewis A, Spurdle AB,
Kedda MA, Khanna KK, kConFab, Mann GJ, Pupo GM, Lakhani SR and
Chenevix-Trench G: Mutation analysis of five candidate genes in
familial breast cancer. Breast Cancer Res Treat. 105:377–389. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chou HC, Chen CH, Lee HS, Lee CZ, Huang
GT, Yang PM, Lee PH and Sheu JC: Alterations of tumour suppressor
gene PPP2R1B in hepatocellular carcinoma. Cancer Lett. 253:138–143.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hemmer S, Wasenius VM, Haglund C, Zhu Y,
Knuutila S, Franssila K and Joensuu H: Alterations in the
suppressor gene PPP2R1B in parathyroid hyperplasias and adenomas.
Cancer Genet Cytogenet. 134:13–17. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yeh LS, Hsieh YY, Chang JG, Chang WW,
Chang CC and Tsai FJ: Mutation analysis of the tumor suppressor
gene PPP2R1B in human cervical cancer. Int J Gynecol Cancer.
17:868–871. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su F, Viros A, Milagre C, Trunzer K,
Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT,
et al: RAS mutations in cutaneous squamous-cell carcinomas in
patients treated with BRAF inhibitors. N Engl J Med. 366:207–215.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Van Raamsdonk CD, Griewank KG, Crosby MB,
Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green
G, Bouvier N, et al: Mutations in GNA11 in uveal melanoma. N Engl J
Med. 363:2191–2199. 2010.PubMed/NCBI
|
|
24
|
Zou Y, Zeng Y, Zhang DF, Zou SH, Cheng YF
and Yao YG: IDH1 and IDH2 mutations are frequent in Chinese
patients with acute myeloid leukemia but rare in other types of
hematological disorders. Biochem Biophys Res Commun. 402:378–383.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu Y, Loukola A, Monni O, Kuokkanen K,
Franssila K, Elonen E, Vilpo J, Joensuu H, Kere J, Aaltonen L and
Knuutila S: PPP2R1B gene in chronic lymphocytic leukemias and
mantle cell lymphomas. Leuk Lymphoma. 41:177–183. 2001. View Article : Google Scholar : PubMed/NCBI
|
